Abstract
The ongoing Early Prostate Cancer (EPC) programme is assessing bicalutamide ('Casodex') 150 mg, either alone or as adjuvant to treatment of curative intent, in patients with localised or locally advanced prostate cancer (n=8113). This paper presents an exploratory analysis of the subgroup of the EPC programme who received radiotherapy with curative intent (n=1370) in order to determine the efficacy (in terms of progression-free survival [PFS]) and tolerability of bicalutamide 150 mg in this setting.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Radiotherapy & Oncology |
Vol/bind | 76 |
Udgave nummer | 1 |
Sider (fra-til) | 4-10 |
Antal sider | 7 |
ISSN | 0167-8140 |
Status | Udgivet - 1 jul. 2005 |